SRI teams with Kalekona to deliver therapies aimed at diagnosing and treating pancreatic cancer and glioblastoma

SRI’s FOX Three peptide platform to deliver precision radionuclide therapy targeted at hard-to-treat tumors.

MENLO PARK, CA, UNITED STATES, October 21, 2025 /EINPresswire.com/ -- SRI today announced that it formed a strategic partnership with Kalekona Radiotheranostics, a biotech startup focused on breakthrough radiopharmaceuticals, to accelerate peptide receptor radionuclide therapy (PRRT) for pancreatic ductal adenocarcinoma and glioblastoma.

“Our FOX Three platform enables rapid, tumor-specific delivery of radionuclides,” said David Parekh, CEO of SRI. “SRI’s multidisciplinary biotech expertise and innovative delivery technology, along with our collaboration with Kalekona, bring new therapeutic approaches to patients with serious cancers faster than ever.”

Radiotheranostics merges nuclear imaging and radionuclide therapy to diagnose and treat cancer in a single, highly targeted workflow. PRRT works like a guided missile to reach its target: a diagnostic version carries a PET-detectable isotope that highlights tumors, while a therapeutic version swaps in a radioisotope that destroys cancer cells.

SRI’s FOX Three Molecular Guidance System (MGS) creates peptide carriers that can be interchanged between two isotopes, providing a seamless transition from detection to treatment.

“MGS peptides locate tumors within minutes, remain bound long enough to provide high-resolution images or deliver the therapeutic payload, and do not harm the surrounding healthy tissue,” said Kathlynn Brown, President of SRI’s Biosciences Division and Chief Science Officer of Kalekona. “This type of delivery will enhance diagnostic precision and targeted treatment while minimizing collateral radiation exposure.”

Historically, PRRT has been limited to neuroendocrine tumors because suitable targeting peptides were scarce. The FOX Three platform generates custom peptides for any cancer type, opening PRRT to pancreatic and brain tumors that lack effective radionuclides.

“Kalekona’s mission is to translate breakthrough radiopharmaceuticals into real-world therapies,” said Ronald H.W. Lorijn, CEO of Kalekona. “SRI’s decades of experience and proven FOX Three platform give us the confidence that we’ll be able to move fast on this important work.”

About SRI

An independent nonprofit R&D institute, SRI has an 80-year history of supporting government and industry customers. SRI delivers impactful technology used by billions of people every day. From AI to quantum, SRI has a successful track record of delivering deep technology to the real world. Headquartered in Silicon Valley, SRI has offices across the US and in Japan. Learn more at www.sri.com.

About Kalekona Radiotheranostics
Kalekona Radiotheranostics develops precision radiopharmaceuticals for hard-to-treat cancers, leveraging novel peptide platforms to create both diagnostic and therapeutic agents.


###

PR Contact | Kelly Brieger | kelly.brieger@sri.com | SRI.com | LinkedIn | YouTube 

Kelly Brieger
https://www.linkedin.com/company/sri-international/mycompany
+1 650-704-1748
email us here
Visit us on social media:
LinkedIn
Facebook
YouTube

Kathlynn Brown, President, Biosciences Division, SRI

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.